Side Effects Evaluation of the Use of Metformin and Glimepiride Combination In Type 2 Diabetes Mellitus Outpatients
DOI:
https://doi.org/10.36733/medicamento.v8i2.3164Keywords:
glimepiride, metformin, side effect of drugs, type 2 diabetes mellitusAbstract
The combination of metformin and glimepiride can significantly reduce fasting blood glucose, post prandial blood glucose, and HbA1c levels. Side effects that often occur in the use of metformin are gastrointestinal disturbances. This study aims to determine the side effects of using a combination of metformin and glimepiride in outpatient type 2 diabetes mellitus at a hospital in Gianyar. This research is an observational research and data collection is done with a cross sectional approach and analyzed using descriptive methods. Data was taken by looking at the patient's medical record, including name, medical record number, gender, age, drugs given, patient diagnosis, and patient complaints during therapy. Sampling used purposive sampling technique with a total of 70 patients who entered the inclusion criteria. The results show that the number of women (62.86%). The most age range suffering from type 2 diabetes mellitus is 56-65 years (52.86%). The highest percentage of people with type 2 diabetes mellitus had a basic education level (40.00%). The side effects obtained from the combination of metformin and glimepiride in patients with type 2 diabetes mellitus at the hospital were nausea and vomiting (31.43%), flatulence (25.71%), fatigue (17.14%), headache (15.72%), and hypoglycemia (10.00%).
References
American Diabetes Association (ADA). (2015). Diagnosis and classification of diabetes Mellitus. American Diabetes Care, 38, 8–16.
American Pharmacist Association. (2017). Drug Information Handbook: A Clinically Relevant Resource for All Healthcare Professionals.
American Pharmacist Association. (2012). Drug Information Handbook with International Trade Names Index 21st edition. (21st ed.). Lexicomp.
Arifin AL. (2011). Panduan Terapi Diabetes Mellitus Tipe 2 Terkini. Sub Bagian Endokrinologi & Metabolisme Bagian / UPF. Ilmu Penyakit Dalam. Fakultas Kedokteran. UNPAD (/ RSUP dr. Hasan Sadikin (ed.)).
Association, A. D. (2017). Standards Of Medical Care In Diabetes.
Furdiyanti, H.N., et. a. (2017). Evaluasi Dosis dan Interaksi Obat Antidiabetika Oral pada Pasien Diabetes Melitus Tipe II. Semarang. Universitas Ngudi Waluyo.
Irawan, I. (2010). Makrovaskular dan MikrovaskularReduction Type Diabetes Mellitus Tipe 2 di Daerah Urban Indonesia (Analisis Data Sekunder Risdeskas 2007). Universitas Indonesia.
Joddy Sutama Putra, R., Achmad, A., & Rachma Pramestutie, H. (2017). Kejadian Efek Samping Potensial Terapi Obat Anti Diabetes Pada Pasien Diabetes Melitus Berdasarkan Algoritme Naranjo. Pharmaceutical Journal of Indonesia, 2(2), 45–50. https://doi.org/10.21776/ub.pji.2017.002.02.3
Kartika, L., & W, S. (2011). Perbandingan Profil Penggunaan Terapi Kombinasi Insulin pada Pasien Diabetes Melitus Tipe 2 di Unit Rawat Inap Rumah Sakit Umum Pusat (RSUP) Sanglah.
Khotimah, K. (2013). Gambaran Faktor Resiko Diabetes Melitus Tipe 2 di Klinik dr. Martha Ungaran. Skripsi, SKM, Program Stdu Kesehatan Masyarakat. Stikes Ngudi Waluyo.
Kroon, L.A. dan Williams, C. (2013). Diabetes Mellitus, dalam: Applied Basic and Clinical Pharmacy.
Ogbru, O., Williams, E., Marks, J. W. (2015). Insulin: Drug Facts, Side Effects, and Dosing.
Oktarlina, R.Z, dan Gumantara, M. P. . (2017). Perbandingan Monoterapi dan Kombinasi Terapi Sulfonilurea-Metformin terhadap Pasien Diabetes Melitus Tipe 2. 6, 55–59.
Perkumpulan Endrokrinologi Indonesia (PERKENI). (2015). Pengelolaan dan pencegahan diabetes melitus di Indonesia. https://doi.org/10.1017/CBO9781107415324.004
Stoppler, M. C. (2015). Glucophage Side Effects Center.
W Udayani, H Meriyani, K. W. (2017). ANALISIS EFEKTIVITAS BIAYA MEDIS LANGSUNG PENGGUNAAN INSULIN DAN INSULIN KOMBINASI OHO PADA PASIEN DM TIPE 2 RAWAT JALAN DI RSUP SANGLAH DENPASAR. 4(1), 18–24.
Zahtamal, dkk. (2007). Faktor-Faktor Risiko Pasien Diabetes Melitus. (23(3)). Berita Kedokteran Masyarakat.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Ni Nyoman Wahyu Udayani, I Gusti Agung Ayu Kusuma Wardani, I Dewa Ayu Anom Yustari Nida
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The copyright holder for the work is the Jurnal Ilmiah Medicamento.
Jurnal Ilmiah Medicamento is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- The licensor cannot revoke these freedoms if you follow the license terms.
Under the following terms:
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so reasonably but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
